Sanofi Adds mRNA Specialist Tidal To Acquisition Spree
Focus Again On Cancer and Immunology
Sanofi has paid out $160m to add to its in-house expertise in mRNA and novel cell therapy technologies.
You may also be interested in...
The UK drug discovery specialist has made slow progress until now, but the Sanofi deal could yield a challenger in the competitive psoriasis field.
Argenx partners with Elektrofi and Iontas; China’s Qilu obtains global rights to Peptron’s antibody-drug conjugate and also ends co-development pact with Quantum Genomics.
Strong sales of Dupixent and its range of vaccines are expected to drive Sanofi’s financial results for the first quarter of 2021, although these are likely to have been adversely affected by currency exchange rate movements. Numerous data readouts are expected in the coming months from pipeline products.